MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Larimar Therapeutics, Inc. (Nasdaq:LRMR)*
Organization & Developments: Larimar Therapeutics
Parents
Larimar Therapeutics, Inc. (Nasdaq:LRMR)*
Children
*Clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
*The company's lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.
2021: Larimar Therapeutics: A Speculative Buy For Their Friedreich's Ataxia Treatment
2024: A Promising Candidate for Friedreich's Ataxia
2024: Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential_seekingalpha.com
2024: Larimar's Friedreich's ataxia program free at last from FDA hold
2025: Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Jumps
Finance & Acquisitions: Larimar Therapeutics
Key People: Larimar Therapeutics